University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Susan M. Chang, MD

Susan M. Chang, MD

Professor in Residence, Department of Neurological Surgery, UCSF
Co-Leader, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

Lai Wan Kan Endowed Chair, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

My research interest is in the development of novel therapies for patients with brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients. I am the principal investigator and co-investigator on more than 15 active clinical trials that evaluate the wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and serve on the coordinating committee for that entity. I have served as a member of the Board of Scientific Directors and currently am a member of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the Helen Diller Family Comprehensive Cancer Center. I am the PI of a P01 grant related to integrating advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma (GBM). For the UCSF Brain Tumor SPORE, I am the clinical co-PI of the overall grant, a member of the Executive Committee, the co-Director of the Biostatistical and Clinical Core and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma.


University of British Columbia, 1981
University of British Columbia, MD, 1985, Medicine
Pasqua Hospital, University of Saskatchewan, Regina, Internship, 1985-1986
Plains Health Centre, Regina, Saskatchewan, Residency, 1986-1987
Toronto General Hospital, U of Toronto, Ontario, Residency, 1987-1989
Princess Margaret Hospital, U of Toronto, Ontario, Residency, 1989-1991
Royal College of Physicians & Surgeons, Canada, FRCPS, 1990, Internal Medicine
Royal College of Physicians & Surgeons, Canada, FRCPS, 1991, Medical Oncology

Professional Experience

  • 1991-1992
    Lecturer, Department of Medicine, University of Toronto, Ontario
  • 1991-1992
    Director of Palliative Care, Department of Medicine, St Michael's Hospital, Toronto, Ontario
  • 1992-1994
    Clinical Instructor, Neuro-Oncology Program, Brain Tumor Research Center, Department of Neurological Surgery, UCSF
  • 1994-1996
    Assistant Clinical Professor, Neuro-Oncology Program, Brain Tumor Research Center, Department of Neurological Surgery, UCSF
  • 1994-present
    Member, Brain Tumor Research Center, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 1996-1998
    Assistant Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 1998-2004
    Associate Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 2003-present
    Vice Chair of Clinical Enterprise, Department of Neurological Surgery, UCSF
  • 2004-present
    Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 2005-present
    Director, Division of Neuro-Oncology, Department of Neurological Surgery, UCSF
  • 2013-present
    Director, Gordon Murray Neuro-Oncology Caregiver Program
  • 2014-present
    Editor in Chief of Neuro-Oncology Practice
  • 2015-present
    Program Leader, Neuro-Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 2014
    UCSF Voice of the Patient Pinnacle Award x 7 years, Press Ganey award for excellence in patient care per division, Hall of Fame
  • 2014
    John J. Mealey Jr. Neuro-Oncology Lectureship

Selected Publications

  1. Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017 Mar 22; 7:44792.
    View on PubMed
  2. Neill E, Luks T, Dayal M, Phillips JJ, Perry A, Jalbert LE, Cha S, Molinaro A, Chang SM, Nelson SJ. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol. 2017 Mar; 132(1):171-179.
    View on PubMed
  3. Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2016 Nov 28; JCO2016707562.
    View on PubMed
  4. Han SJ, Chang SM, Berger MS. Laser Ablation vs Open Resection for Deep-Seated Tumors: The Case for Open Resection. Neurosurgery. 2016 Aug; 63 Suppl 1:10-4.
    View on PubMed
  5. Barajas RF, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha S. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Acad Radiol. 2016 Sep; 23(9):1073-82.
    View on PubMed
  6. Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev. 2016 Apr 16.
    View on PubMed
  7. Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, Molinaro AM, Berger MS, Chang SM, Nelson SJ. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol. 2016 Aug; 18(8):1169-79.
    View on PubMed
  8. Chaikriangkrai K, Maragiannis D, Belousova T, Little S, Nabi F, Mahmarian J, Chang SM. Clinical Utility of Multidetector Computed Tomography in Redo Valve Procedures. J Card Surg. 2016 Mar; 31(3):139-46.
    View on PubMed
  9. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200.
    View on PubMed
  10. Chang SM, Cahill DP, Aldape KD, Mehta MP. Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. Am Soc Clin Oncol Educ Book. 2016; 35:75-81.
    View on PubMed
  11. Wen Q, Jalilian L, Lupo JM, Li Y, Roy R, Molinaro AM, Chang SM, Prados M, Butowski N, Clarke J, Nelson SJ. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec; 8(6):446-55.
    View on PubMed
  12. Maragiannis D, Jackson MS, Igo SR, Schutt RC, Connell P, Grande-Allen J, Barker CM, Chang SM, Reardon MJ, Zoghbi WA, Little SH. Replicating Patient-Specific Severe Aortic Valve Stenosis With Functional 3D Modeling. Circ Cardiovasc Imaging. 2015 Oct; 8(10).
    View on PubMed
  13. Wen Q, Kelley DA, Banerjee S, Lupo JM, Chang SM, Xu D, Hess CP, Nelson SJ. Clinically feasible NODDI characterization of glioma using multiband EPI at 7 T. Neuroimage Clin. 2015; 9:291-9.
    View on PubMed
  14. Chaikriangkrai K, Chebrolu L, Bhatti S, Chang SM. Diagnosis of ischemia in hypertrophic cardiomyopathy: role of computed tomography and nuclear stress testing. Curr Opin Cardiol. 2015 Sep; 30(5):483-92.
    View on PubMed
  15. Maragiannis D, Schutt RC, Gramze NL, Chaikriangkrai K, McGregor K, Chin K, Nabi F, Little SH, Nagueh SF, Chang SM. Association of Left Ventricular Diastolic Dysfunction with Subclinical Coronary Atherosclerotic Disease Burden Using Coronary Artery Calcium Scoring. J Atheroscler Thromb. 2015 Dec 1; 22(12):1278-86.
    View on PubMed
  16. Chaikriangkrai K, Nabi F, Mahmarian JJ, Chang SM. Additive prognostic value of coronary artery calcium score and renal function in patients with acute chest pain without known coronary artery disease: up to 5-year follow-up. Int J Cardiovasc Imaging. 2015 Dec; 31(8):1619-26.
    View on PubMed
  17. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53; discussion 253.
    View on PubMed
  18. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  19. Lupo JM, Molinaro AM, Essock-Burns E, Butowski N, Chang SM, Cha S, Nelson SJ. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma†. Neuro Oncol. 2016 Jan; 18(1):87-95.
    View on PubMed
  20. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015 Jun 25; 372(26):2499-508.
    View on PubMed

Go to UCSF Profiles, powered by CTSI